Identification of Orthosteric and Allosteric Site Mutations in M2 Muscarinic Acetylcholine Receptors That Contribute to Ligand-selective Signaling Bias*

Muscarinic acetylcholine receptors contain at least one allosteric site that is topographically distinct from the acetylcholine, orthosteric binding site. Although studies have investigated the basis of allosteric modulation at these receptors, less is known about putative allosteric ligands that activate the receptor in their own right. We generated M2 muscarinic acetylcholine receptor mutations in either the orthosteric site in transmembrane helices 3 and 6 (TM3 and -6) or part of an allosteric site involving the top of TM2, the second extracellular (E2) loop, and the top of TM7 and investigated their effects on the binding and function of the novel selective (putative allosteric) agonists (AC-42 (4-n-butyl-1-(4-(2-methylphenyl)-4-oxo-1-butyl)piperidine HCl), 77-LH-28-1 (1-(3-(4-butyl-1-piperidinyl)propyl)-3,3-dihydro-2(1H)-quinolinone), and N-desmethylclozapine) as well as the bitopic orthosteric/allosteric ligand, McN-A-343 (4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium). Four classes of agonists were identified, depending on their response to the mutations, suggesting multiple, distinct modes of agonist-receptor interaction. Interestingly, with the exception of 77-LH-28-1, allosteric site mutations had no effect on the affinity of any of the agonists tested, but some mutations in the E2 loop influenced the efficacy of both orthosteric and novel selective agonists, highlighting a role for this region of the receptor in modulating activation status. Two point mutations (Y1043.33A (Ballesteros and Weinstein numbers in superscript) in the orthosteric and Y177A in the allosteric site) unmasked ligand-selective and signaling pathway-selective effects, providing evidence for the existence of pathway-specific receptor conformations. Molecular modeling of 77-LH-28-1 and N-desmethylclozapine yielded novel binding poses consistent with the possibility that the functional selectivity of such agents may arise from a bitopic mechanism.

[1]  J. Wess,et al.  Conformational Changes That Occur during M3Muscarinic Acetylcholine Receptor Activation Probed by the Use of an in Situ Disulfide Cross-linking Strategy* , 2002, The Journal of Biological Chemistry.

[2]  A. Deutch,et al.  Novel Selective Allosteric Activator of the M1 Muscarinic Acetylcholine Receptor Regulates Amyloid Processing and Produces Antipsychotic-Like Activity in Rats , 2008, The Journal of Neuroscience.

[3]  K. Mohr,et al.  Using a radioalloster to test predictions of the cooperativity model for gallamine binding to the allosteric site of muscarinic acetylcholine M(2) receptors. , 1999, Molecular pharmacology.

[4]  C. Langmead,et al.  Probing the Molecular Mechanism of Interaction between 4-n-Butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the Muscarinic M1 Receptor: Direct Pharmacological Evidence That AC-42 Is an Allosteric Agonist , 2006, Molecular Pharmacology.

[5]  Arthur Christopoulos,et al.  Critical Role for the Second Extracellular Loop in the Binding of Both Orthosteric and Allosteric G Protein-coupled Receptor Ligands* , 2007, Journal of Biological Chemistry.

[6]  K. Mohr,et al.  Interactions of orthosteric and allosteric ligands with [3H]dimethyl-W84 at the common allosteric site of muscarinic M2 receptors. , 2003, Molecular pharmacology.

[7]  Arthur Christopoulos,et al.  Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs. , 2009, Molecular interventions.

[8]  J. Wess,et al.  Multiple Residues in the Second Extracellular Loop Are Critical for M3 Muscarinic Acetylcholine Receptor Activation* , 2007, Journal of Biological Chemistry.

[9]  A. Christopoulos Assessing the distribution of parameters in models of ligand-receptor interaction: to log or not to log. , 1998, Trends in pharmacological sciences.

[10]  R. Abagyan,et al.  Biased probability Monte Carlo conformational searches and electrostatic calculations for peptides and proteins. , 1994, Journal of molecular biology.

[11]  Arthur Christopoulos,et al.  A Novel Mechanism of G Protein-coupled Receptor Functional Selectivity , 2008, Journal of Biological Chemistry.

[12]  Christopher J Langmead,et al.  Mutagenic Mapping Suggests a Novel Binding Mode for Selective Agonists of M1 Muscarinic Acetylcholine Receptors , 2009, Molecular Pharmacology.

[13]  C. Langmead,et al.  Structure-Function Studies of Allosteric Agonism at M2 Muscarinic Acetylcholine Receptors , 2007, Molecular Pharmacology.

[14]  U. Holzgrabe,et al.  Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  R. Paschke,et al.  Contacts between Extracellular Loop Two and Transmembrane Helix Six Determine Basal Activity of the Thyroid-stimulating Hormone Receptor* , 2007, Journal of Biological Chemistry.

[16]  J. Vorlíček,et al.  Positive cooperativity in the binding of alcuronium and N-methylscopolamine to muscarinic acetylcholine receptors. , 1990, Molecular pharmacology.

[17]  P. Sexton,et al.  Application of a Kinetic Model to the Apparently Complex Behavior of Negative and Positive Allosteric Modulators of Muscarinic Acetylcholine Receptors , 2004, Journal of Pharmacology and Experimental Therapeutics.

[18]  U. Hacksell,et al.  Discovery of an ectopic activation site on the M(1) muscarinic receptor. , 2002, Molecular pharmacology.

[19]  Richard M. Eglen,et al.  Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development , 2007, Nature Reviews Drug Discovery.

[20]  C. Felder Muscarinic acetylcholine receptors: signal transduction through multiple effectors , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  R. Eglen,et al.  Therapeutic opportunities from muscarinic receptor research. , 2001, Trends in pharmacological sciences.

[22]  J. Proska,et al.  Positive allosteric action of eburnamonine on cardiac muscarinic acetylcholine receptors. , 1996, European journal of pharmacology.

[23]  E C Hulme,et al.  The Functional Topography of Transmembrane Domain 3 of the M1 Muscarinic Acetylcholine Receptor, Revealed by Scanning Mutagenesis* , 1999, The Journal of Biological Chemistry.

[24]  Roberto Maass-Moreno,et al.  Fitting Models to Biological Data Using Linear and Nonlinear Regression: A Practical Guide to Curve Fitting.ByHarvey Motulskyand, Arthur Christopoulos.Oxford and New York: Oxford University Press. $65.00 (hardcover); $29.95 (paper). 351 p; ill.; index. ISBN: 0–19–517179–9 (hc); 0–19–517180–2 (pb). 2 , 2005 .

[25]  Zhi-Liang Lu,et al.  Scanning mutagenesis studies of the M1 muscarinic acetylcholine receptor. , 2003 .

[26]  F. Mitchelson,et al.  THE INHIBITORY EFFECT OF GALLAMINE ON MUSCARINIC RECEPTORS , 1976, British journal of pharmacology.

[27]  K. Jakobs,et al.  Activation of solubilized G-proteins by muscarinic acetylcholine receptors. , 1992, Cellular signalling.

[28]  Kenneth A. Jacobson,et al.  The Role of Amino Acids in Extracellular Loops of the Human P2Y1 Receptor in Surface Expression and Activation Processes* , 1999, The Journal of Biological Chemistry.

[29]  E. Hulme,et al.  Alanine-scanning mutagenesis of transmembrane domain 6 of the M(1) muscarinic acetylcholine receptor suggests that Tyr381 plays key roles in receptor function. , 1999, Molecular pharmacology.

[30]  H Gobind Khorana,et al.  Rhodopsin structure, dynamics, and activation: a perspective from crystallography, site-directed spin labeling, sulfhydryl reactivity, and disulfide cross-linking. , 2003, Advances in protein chemistry.

[31]  K. Gregory,et al.  Allosteric Modulation of Muscarinic Acetylcholine Receptors , 2007, Current neuropharmacology.

[32]  Xi-Ping Huang,et al.  Critical Amino Acid Residues of the Common Allosteric Site on the M2 Muscarinic Acetylcholine Receptor: More Similarities than Differences between the Structurally Divergent Agents Gallamine and Bis(ammonio)alkane-Type Hexamethylene-bis-[dimethyl-(3-phthalimidopropyl)ammonium]dibromide , 2005, Molecular Pharmacology.

[33]  W. Sadee,et al.  Allosteric modulation of muscarinic receptor signaling: alcuronium-induced conversion of pilocarpine from an agonist into an antagonist. , 2002, The Journal of pharmacology and experimental therapeutics.

[34]  O. Wassermann,et al.  Inhibition of the actions of carbachol and DFP on guinea pig isolated atria by alkane-bis-ammonium compounds. , 1969, European journal of pharmacology.

[35]  P. Sexton,et al.  Mechanisms of ERK1/2 regulation by seven-transmembrane-domain receptors. , 2006, Current pharmaceutical design.

[36]  B. Roth,et al.  New Insights into the Function of M4 Muscarinic Acetylcholine Receptors Gained Using a Novel Allosteric Modulator and a DREADD (Designer Receptor Exclusively Activated by a Designer Drug) , 2008, Molecular Pharmacology.

[37]  A. Christopoulos,et al.  Cellular Signaling Mechanisms for Muscarinic Acetylcholine Receptors , 2003 .

[38]  C. Langmead,et al.  Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox. , 2006, Trends in pharmacological sciences.

[39]  J. Wess,et al.  Functional role in ligand binding and receptor activation of an asparagine residue present in the sixth transmembrane domain of all muscarinic acetylcholine receptors. , 1994, The Journal of biological chemistry.

[40]  John Ellis,et al.  Mutational Disruption of a Conserved Disulfide Bond in Muscarinic Acetylcholine Receptors Attenuates Positive Homotropic Cooperativity between Multiple Allosteric Sites and Has Subtype-Dependent Effects on the Affinities of Muscarinic Allosteric Ligands , 2007, Molecular Pharmacology.

[41]  U. Holzgrabe,et al.  Allosteric Small Molecules Unveil a Role of an Extracellular E2/Transmembrane Helix 7 Junction for G Protein-coupled Receptor Activation* , 2007, Journal of Biological Chemistry.

[42]  S. Lazareno,et al.  Probing of the location of the allosteric site on m1 muscarinic receptors by site-directed mutagenesis. , 1995, Molecular pharmacology.

[43]  J. Black,et al.  Operational models of pharmacological agonism , 1983, Proceedings of the Royal Society of London. Series B. Biological Sciences.

[44]  P Ghanouni,et al.  Agonist-induced conformational changes in the G-protein-coupling domain of the β2 adrenergic receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[45]  H. Khorana,et al.  Requirement of Rigid-Body Motion of Transmembrane Helices for Light Activation of Rhodopsin , 1996, Science.

[46]  H. Tecle,et al.  Mutations of aspartate 103 in the Hm2 receptor and alterations in receptor binding properties of muscarinic agonists. , 1995, Life sciences.

[47]  K. Page,et al.  Scanning mutagenesis identifies amino acid side chains in transmembrane domain 5 of the M(1) muscarinic receptor that participate in binding the acetyl methyl group of acetylcholine. , 2000, Molecular pharmacology.

[48]  J. Ellis,et al.  Site-directed mutagenesis reveals two epitopes involved in the subtype selectivity of the allosteric interactions of gallamine at muscarinic acetylcholine receptors. , 1999, Molecular pharmacology.

[49]  H Weinstein,et al.  Agonists induce conformational changes in transmembrane domains III and VI of the β2 adrenoceptor , 1997, The EMBO journal.

[50]  P. Sexton,et al.  Molecular Mechanisms of Action and In Vivo Validation of an M4 Muscarinic Acetylcholine Receptor Allosteric Modulator with Potential Antipsychotic Properties , 2010, Neuropsychopharmacology.

[51]  Arthur Christopoulos,et al.  Functional Selectivity and Classical Concepts of Quantitative Pharmacology , 2007, Journal of Pharmacology and Experimental Therapeutics.

[52]  S. Lazareno,et al.  Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. , 1995, Molecular pharmacology.

[53]  Thomas M Frimurer,et al.  Overlapping Binding Site for the Endogenous Agonist, Small-Molecule Agonists, and Ago-allosteric Modulators on the Ghrelin Receptor , 2009, Molecular Pharmacology.

[54]  J. Wess,et al.  Use of an in situ disulfide cross-linking strategy to study the dynamic properties of the cytoplasmic end of transmembrane domain VI of the M3 muscarinic acetylcholine receptor. , 2006, Biochemistry.

[55]  M. Brann,et al.  Identification of a Ligand-dependent Switch within a Muscarinic Receptor* , 1998, The Journal of Biological Chemistry.

[56]  R. Stevens,et al.  High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein–Coupled Receptor , 2007, Science.

[57]  C. Strader,et al.  Conserved aspartic acid residues 79 and 113 of the beta-adrenergic receptor have different roles in receptor function. , 1988, The Journal of biological chemistry.

[58]  J. Wess,et al.  Site‐directed mutagenesis of the m3 muscarinic receptor: identification of a series of threonine and tyrosine residues involved in agonist but not antagonist binding. , 1991, The EMBO journal.

[59]  M. Whittington,et al.  Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77‐LH‐28‐1 , 2008, British journal of pharmacology.

[60]  F. Ehlert,et al.  Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. , 1988, Molecular pharmacology.

[61]  C. Guenet,et al.  Site-directed mutagenesis of the putative human muscarinic M2 receptor binding site. , 1999, European journal of pharmacology.

[62]  J. Klco,et al.  Essential role for the second extracellular loop in C5a receptor activation , 2005, Nature Structural &Molecular Biology.

[63]  M. Eck,et al.  Role of acidic amino acids in the allosteric modulation by gallamine of antagonist binding at the m2 muscarinic acetylcholine receptor. , 1994, Molecular pharmacology.

[64]  J. Wess,et al.  Pronounced Conformational Changes following Agonist Activation of the M3 Muscarinic Acetylcholine Receptor* , 2005, Journal of Biological Chemistry.

[65]  K. Gregory,et al.  Characterization of serotonin 5‐HT2C receptor signaling to extracellular signal‐regulated kinases 1 and 2 , 2005, Journal of neurochemistry.

[66]  K. Mohr,et al.  Allosteric Interactions with Muscarinic Acetylcholine Receptors: Complex Role of the Conserved Tryptophan M2422Trp in a Critical Cluster of Amino Acids for Baseline Affinity, Subtype Selectivity, and Cooperativity , 2006, Molecular Pharmacology.

[67]  John Ellis,et al.  Allosteric site on muscarinic acetylcholine receptors: identification of two amino acids in the muscarinic M2 receptor that account entirely for the M2/M5 subtype selectivities of some structurally diverse allosteric ligands in N-methylscopolamine-occupied receptors. , 2003, Molecular pharmacology.

[68]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[69]  J. Ballesteros,et al.  [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .

[70]  N. Birdsall,et al.  Propylbenzilylcholine mustard labels an acidic residue in transmembrane helix 3 of the muscarinic receptor. , 1989, The Journal of biological chemistry.

[71]  M. Brann,et al.  Use of chimeric muscarinic receptors to investigate epitopes involved in allosteric interactions. , 1993, Molecular pharmacology.

[72]  K. Mohr,et al.  Allosteric site on muscarinic acetylcholine receptors: a single amino acid in transmembrane region 7 is critical to the subtype selectivities of caracurine V derivatives and alkane-bisammonium ligands. , 2002, Molecular pharmacology.

[73]  L. Bačáková,et al.  Subtype selectivity of the positive allosteric action of alcuronium at cloned M1-M5 muscarinic acetylcholine receptors. , 1995, The Journal of pharmacology and experimental therapeutics.

[74]  P. Jeffrey Conn,et al.  N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-d-aspartate receptor activity , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[75]  J. Wess,et al.  Distinct Structural Changes in a G Protein-coupled Receptor Caused by Different Classes of Agonist Ligands* , 2007, Journal of Biological Chemistry.

[76]  J W Saldanha,et al.  Transmembrane Domains 4 and 7 of the M1Muscarinic Acetylcholine Receptor Are Critical for Ligand Binding and the Receptor Activation Switch* , 2001, The Journal of Biological Chemistry.

[77]  G. Liapakis,et al.  Constitutive Activation of the β2 Adrenergic Receptor Alters the Orientation of Its Sixth Membrane-spanning Segment* , 1997, The Journal of Biological Chemistry.

[78]  H. Khorana,et al.  Structure and function in rhodopsin: replacement by alanine of cysteine residues 110 and 187, components of a conserved disulfide bond in rhodopsin, affects the light-activated metarhodopsin II state. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[79]  M. Brann,et al.  Structural Requirements of Transmembrane Domain 3 for Activation by the M1 Muscarinic Receptor Agonists AC-42, AC-260584, Clozapine, and N-Desmethylclozapine: Evidence for Three Distinct Modes of Receptor Activation , 2006, Molecular Pharmacology.